China, Sep-10-2018
Central South University Xiangya – Yaoyuan Pharma Precision Medicine Research Center has just been officially founded today. This is yet another newly established world class research center in Hunan province of China, which is expected to bring breakthrough in the fields of precision medicine, medical risk analysis and big-data clinical trial researches. Leadership and officials from the university, the Hunan Province health, science, food and drug departments attended the unveiling ceremony and gave speeches.
Central South University Xiangya – Yaoyuan Pharma Precision Medicine Research Center is collaboratively founded by Drug Clinical Review Technology National and Regional Engineering Laboratory, Yaoyuan–Academy for pharma innovation, Shanghai Jiao Tong – Yale Biostatistics Center, Hunan Strategical Alliance of Drug Review Industrial Technical Innovation, and three Xiangya Hospitals. The center has summoned experts from famous universities in United States, United Kingdom, Canada, Australia and from fortune 500 companies including scholars from Chinese Academy of Science and “Thousand-Man-Plan”, mainly focusing on drug risk clinical review big-data research, data driven clinical decision support system, information of international medical and biopharma development, and the universal assessment standard for generic drugs in China.
Following the unveiling ceremony, it was the first Academic Forum of Precision Medicine at Central South University. 3 keynote speakers have given academic presentations. Professor Academician Honghao Zhou from Central South University gave a talk of “Individualized (precision) Medicine’s Present and Future”. Professor Academician Timothy R. Billiar from University of Pittsburg Medical School and Central South University Vascular Disease Translational Medical Center gave presentation “The Clinical Decision Support for Trauma Patients’ Risk Analysis”. Dean Hui Lue of Shanghai Jiao Tong University department of bioinformatics and biostatistics and Shanghai Jiao Tong – Yale Biostatistics Center gave a talk of “Data Driven Biomedical Research and Application”.
Precision medicine is also known as individual medicine, which is designed to optimize efficiency or therapeutic benefit for particular groups of patients. By using genetic or molecular profiling, doctors may precisely prescribe a type or a dosage of a drug improving the therapeutic outcome while minimizing side effects and the cost. Dr. Honghao Zhou as a pioneer of medical genomics research in China, was the first to introduced the concept of individual medicine as well as its clinical applications. Nowadays, individual medicine and therapy has become one of the most effective therapeutic methods and one of the most popular research topics for malignant tumor, hypertension, diabetes and other major chronical diseases.
The Precision Medicine Research Center has established a universal assessment standard platform for generic drugs, launched the first research in China and in Hunan on universal assessment standard for generic drugs, begun a cohort study on the current conditions of drug induced diseases, built a clinical database for high-risk population and high-risk drugs, constructed a risk prediction and quantitative recognition model for relevant individuals and drugs using big-data extraction algorism. The center has utilized the resources from Central South University, Xiangya Hospitals, and pharmaceutical companies with technologies in medical genomics, metabolism and precision medical testing, in order to facilitate the translational researches in individual medicine to help the Chinese people use medicine more safely and reasonably.
